Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.
Sehgal ANA, Safran J, Kratzer B, Gattinger P, Stieger RB, Musiejovsky L, Trapin D, Ettel P, Körmöczi U, Rottal A, Borochova K, Dorofeeva Y, Tulaeva I, Weber M, Grabmeier-Pfistershammer K, Perkmann T, Wiedermann U, Valenta R, Pickl WF. Sehgal ANA, et al. Vaccines (Basel). 2024 Apr 1;12(4):377. doi: 10.3390/vaccines12040377. Vaccines (Basel). 2024. PMID: 38675759 Free PMC article.
Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma.
Kratzer B, Trapin D, Gattinger P, Oberhofer T, Sehgal ANA, Waidhofer-Söllner P, Rottal A, Körmöczi U, Grabmeier-Pfistershammer K, Kopetzky GH, Tischer F, Valenta R, Pickl WF. Kratzer B, et al. Among authors: sehgal ana. Vaccines (Basel). 2022 Feb 27;10(3):374. doi: 10.3390/vaccines10030374. Vaccines (Basel). 2022. PMID: 35335006 Free PMC article.
Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model.
Gattinger P, Kratzer B, Sehgal ANA, Ohradanova-Repic A, Gebetsberger L, Tajti G, Focke-Tejkl M, Schaar M, Fuhrmann V, Petrowitsch L, Keller W, Högler S, Stockinger H, Pickl WF, Valenta R. Gattinger P, et al. Among authors: sehgal ana. Vaccines (Basel). 2024 Feb 23;12(3):229. doi: 10.3390/vaccines12030229. Vaccines (Basel). 2024. PMID: 38543863 Free PMC article.
Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post-infection and post-vaccination cellular SARS-CoV-2-specific immune response.
Kratzer B, Schlax LC, Gattinger P, Waidhofer-Söllner P, Trapin D, Tauber PA, Sehgal ANA, Körmöczi U, Rottal A, Feichter M, Oberhofer T, Grabmeier-Pfistershammer K, Borochova K, Dorofeeva Y, Tulaeva I, Weber M, Mühl B, Kropfmüller A, Negrin B, Kundi M, Valenta R, Pickl WF. Kratzer B, et al. Among authors: sehgal ana. Allergy. 2022 Nov;77(11):3408-3425. doi: 10.1111/all.15406. Epub 2022 Jul 19. Allergy. 2022. PMID: 35690994 Free PMC article.
Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation.
Garner-Spitzer E, Wagner A, Gudipati V, Schoetta AM, Orola-Taus M, Kundi M, Kunert R, Mayrhofer P, Huppa JB, Stockinger H, Carsetti R, Gattinger P, Valenta R, Kratzer B, Sehgal ANA, Pickl WF, Reinisch W, Novacek G, Wiedermann U. Garner-Spitzer E, et al. Among authors: sehgal ana. EBioMedicine. 2023 Oct;96:104788. doi: 10.1016/j.ebiom.2023.104788. Epub 2023 Sep 4. EBioMedicine. 2023. PMID: 37672867 Free PMC article.
Glycopeptide Antibiotics Impair Neutrophil Effector Functions.
Ettel P, Sehgal ANA, Harrison N, Pickl WF, Grabmeier-Pfistershammer K. Ettel P, et al. Among authors: sehgal ana. Int Arch Allergy Immunol. 2023;184(9):932-948. doi: 10.1159/000530865. Epub 2023 Jun 15. Int Arch Allergy Immunol. 2023. PMID: 37321197 Free article.
The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Sehgal ANA, Tauber PA, Stieger RB, Kratzer B, Pickl WF. Sehgal ANA, et al. Int Arch Allergy Immunol. 2024;185(3):286-300. doi: 10.1159/000533677. Epub 2023 Dec 12. Int Arch Allergy Immunol. 2024. PMID: 38086339 Free PMC article. Review.